Heart Disease News and Research

Latest Heart Disease News and Research

Boston Scientific completes enrollment in comparison trial of SYNERGY Stent to PROMUS Element Stent

Boston Scientific Corporation today announced the completion of patient enrollment in the EVOLVE clinical trial, which is designed to assess the safety and performance of the Company's fourth-generation SYNERGY™ Coronary Stent. The randomized, single-blind, non-inferiority trial will compare the SYNERGY Stent to the PROMUS Element™ Everolimus-Eluting Coronary Stent in patients with a single de novo native coronary artery lesion.

24 Jan 2011

Blue Cross and Blue Shield of Florida reduces IT costs with BMC software

With the help of BMC Software, Blue Cross and Blue Shield of Florida (BCBSF) is reducing costs while preparing for the new demands healthcare reform will bring to IT.

24 Jan 2011

Methodist DeBakey Heart & Vascular Center chosen for critical percutaneous heart valve study

The Methodist DeBakey Heart & Vascular Center was chosen today as a site for a critical percutaneous heart valve study. As part of the research study, Methodist physicians will replace diseased cardiac valves through a single, tiny puncture hole in the research subject's groin.

24 Jan 2011

NHLBI, HeartWare award $13.3M to study benefits of heart devices for heart failure

The University of Michigan Cardiovascular Center and the University of Pittsburgh have been awarded $13.3 million to explore the potential benefits of heart devices for the large and growing group of Americans with heart failure.

24 Jan 2011

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Thursday, January 20, 2011, it submitted a Post Approval Supplement containing data supporting the removal of the Indium-111 ZEVALIN® pre-treatment imaging evaluation, more commonly referred to as the "bioscan" requirement.

24 Jan 2011

KineMed's fibrosis research program featured in Nature Medicine

KineMed Inc.'s fibrosis research program, which aims to advance the discovery and development of drugs to treat this major disease, is featured in the January edition of Nature Medicine.

24 Jan 2011

AnC Bio Holdings invests $4 million in Bioheart

Bioheart, Inc. announced today that it has entered into an agreement with AnC Bio Holdings, Inc., a South Korean biomedical company, and one of its U.S. agents for a $4 million equity investment. Bioheart has designated proceeds from the investment to advance the current clinical evaluation of its cell therapies for treating heart failure and related cardiac diseases.

24 Jan 2011

Positive interim data from ongoing V5 Phase IIb imm01 trial against tuberculosis

Immune Network, a company in the business of development and commercialization of immune therapies, announced today that its newly acquired business, Immunitor, has published interim data from the ongoing Phase IIb imm01 clinical trial of V5 in tuberculosis conducted at its second site in Ukraine.

24 Jan 2011

China Shenghuo's Lixuwang product recieves Chinese Well-Known Trademark Honor

China Shenghuo Pharmaceutical Holdings, a China-based pharmaceutical company engaged in the research, development, manufacture, and marketing of Traditional Chinese Medicine, nutritional supplement and cosmetic products, today announced that "Lixuwang", the trademark of its best selling product, Xuesaitong Capsule, was awarded the Chinese Well-Known Trademark Honor by the State Administration for Industry and Commerce of China.

24 Jan 2011

Scientists ignore relevant drug clinical trials when conducting new research on same topic

The vast majority of already published and relevant clinical trials of a given drug, device or procedure are routinely ignored by scientists conducting new research on the same topic, a new Johns Hopkins study suggests.

24 Jan 2011

Boehringer Ingelheim's Prazaxa receives Japanese approval for stroke prevention in AF patients

The Ministry of Health, Labour and Welfare in Japan today approved dabigatran etexilate, Boehringer Ingelheim's novel, oral direct thrombin inhibitor under the brand name Prazaxa for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation marking the first approval of a novel oral anticoagulant in the Asia-Pacific region and specifically Japan in nearly 50 years.

24 Jan 2011

Stusy: HEPA filters may help reduce pollution-related cardiovascular health risks

Using inexpensive air filters may help reduce cardiovascular disease risk that results from exposure to air pollution, according to researchers from Canada, who studied healthy adultsliving in a small community in British Columbia where wood burning stoves are the main sources of pollution.

24 Jan 2011

FDA approves On-X AAP with Vascutek Gelweave Valsalva Graft

On-X Life Technologies, announced today that it has received approval from the U.S. Food and Drug Administration to market the On-X Ascending Aortic Prosthesis with the Vascutek Gelweave Valsalva Graft.

23 Jan 2011

Australia’s Healthy Weight Week

The Dietitians Association of Australia (DAA) has launched Australia’s Healthy Weight Week (AHWW) on Sunday in an attempt to make people choose a healthier lifestyle of eating better and exercising more.

23 Jan 2011

First U.S. implant of RespiCardia System for treatment of sleep apnea

Cardiac Concepts, announced today the first U.S. clinical implant of the RespiCardia System at The Ohio State University Medical Center, Columbus, Ohio.

21 Jan 2011

Everist Genomics reports positive results from OncoDefender-CRC assay external validation study

Everist Genomics, a prognostics company focused on developing gene-based molecular assays for the prediction of cancer recurrence, today announced the positive results of the first external validation study of its OncoDefender-CRC colorectal cancer recurrence test. The study is being conducted by Mayo Validation Support Services, and is being coordinated with investigators and resources from all three Mayo Clinic sites.

21 Jan 2011

$Medicare reimbursed for only a fraction of the services recommended by government task force, study finds$

Medicare reimbursed for only a fraction of the services recommended by government task force, study finds

Health care reform should be able to mend a disconnect that has existed between the recommendations of the U.S. Preventive Services Task Force (USPSTF), a task force charged by the government to review clinical preventive health services for older adults, and Medicare coverage for those services, a new UCLA-led study finds.

21 Jan 2011

What protects certain diabetics from complications?

Much research has been carried out on why diabetics develop complications. Now researchers are asking the question the other way around. They want to know why some diabetic patients do not develop complications. What is it that protects them? The PROLONG study could provide the answer.

21 Jan 2011

RBM, SMA Foundation collaborate to develop plasma protein biomarkers for spinal muscular atrophy

The Spinal Muscular Atrophy Foundation and Rules-Based Medicine, announced today that they have reached the first milestone in a program to develop a panel of plasma protein biomarkers for SMA using RBM's Multi-Analyte Profiling technology platform.

21 Jan 2011

Pervasis to present PVS-10200 interim data from Phase 1/2 PAD clinical study at IC3D

Pervasis Therapeutics, Inc. today announced it will present interim data from the company's Phase 1/2 clinical study of PVS-10200, an investigational cell-based therapy under development to prevent restenosis in patients with peripheral arterial disease (PAD) who undergo an angioplasty and stent procedure in the superficial femoral artery.

21 Jan 2011

Heart Disease News and Research

Latest Heart Disease News and Research

Boston Scientific completes enrollment in comparison trial of SYNERGY Stent to PROMUS Element Stent

Blue Cross and Blue Shield of Florida reduces IT costs with BMC software

Methodist DeBakey Heart & Vascular Center chosen for critical percutaneous heart valve study

NHLBI, HeartWare award $13.3M to study benefits of heart devices for heart failure

Spectrum submits Post Approval Supplement for removal of bioscan requirement for Indium-111 ZEVALIN

KineMed's fibrosis research program featured in Nature Medicine

AnC Bio Holdings invests $4 million in Bioheart

Positive interim data from ongoing V5 Phase IIb imm01 trial against tuberculosis

China Shenghuo's Lixuwang product recieves Chinese Well-Known Trademark Honor

Scientists ignore relevant drug clinical trials when conducting new research on same topic

Boehringer Ingelheim's Prazaxa receives Japanese approval for stroke prevention in AF patients

Stusy: HEPA filters may help reduce pollution-related cardiovascular health risks

FDA approves On-X AAP with Vascutek Gelweave Valsalva Graft

Australia’s Healthy Weight Week

First U.S. implant of RespiCardia System for treatment of sleep apnea

Everist Genomics reports positive results from OncoDefender-CRC assay external validation study

Medicare reimbursed for only a fraction of the services recommended by government task force, study finds

What protects certain diabetics from complications?

RBM, SMA Foundation collaborate to develop plasma protein biomarkers for spinal muscular atrophy

Pervasis to present PVS-10200 interim data from Phase 1/2 PAD clinical study at IC3D

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

The importance of ketones from a clinical and medical perspective

Heart Disease News and Research

Latest Heart Disease News and Research

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

The importance of ketones from a clinical and medical perspective

Newsletters you may be interested in